Brought to you by 
Series H raises $50mm for Ironwood Pharmaceuticals
07 Oct 2008
Executive Summary
Ironwood Pharmaceuticals (formerly Microbia; cardiovascular and gastrointestinal therapeutics) brought in $50mm via its Series H financing round led by Morgan Stanley Investment Management with additional participation from unnamed returning shareholders. The company will use the funds to continue Phase III trials of linaclotide for irritable bowel syndrome with constipation and chronic constipation. Ironwood is developing the compound with partner Forest Laboratories. To date, Ironwood has raised about $280mm.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series H raises $50mm for Ironwood Pharmaceuticals
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice